The drug safety and risk management advisory committee: A case study of meeting frequency, content, and outcomes before and after FDAAA

Medical Care

Volumn 50, Issue 11, 2012, Pages 970-986

  Morrato, Elaine H ^a,b   Ling, Sarah B ^c  

^a Global Health and Health Disparities   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Des Moines University College of Osteopathic Medicine   (United States)

Author keywords

drug safety; pharmaceutical policy; regulation; risk assessment

Indexed keywords

ALENDRONIC ACID; ALOSETRON; APROTININ; DEXTROMETHORPHAN; FENTANYL CITRATE; FERRIC CARBOXYMALTOSE; FOSPHENYTOIN SODIUM; HYDROMORPHONE; IBANDRONIC ACID; ISOTRETINOIN; MORPHINE SULFATE PLUS NALTREXONE; NATALIZUMAB; NICOTINIC ACID PLUS OXYCODONE; OXYBATE SODIUM; OXYCODONE; PHENYTOIN; RISEDRONIC ACID; ROSIGLITAZONE; TAZAROTENE; TELITHROMYCIN; ZOLEDRONIC ACID;

ADVISORY COMMITTEE; ARTICLE; CARDIOVASCULAR RISK; DECISION MAKING; DRUG ABUSE; DRUG APPROVAL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HUMAN; MEDICATION ERROR; PATIENT INFORMATION; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK MANAGEMENT;

ADVISORY COMMITTEES; HUMANS; ORGANIZATIONAL CASE STUDIES; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867737863     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31826c872d     Document Type: Article

References (25)

1. U.S. Food and Drug Administration. What we do. 2010. Available at: http://www.fda.gov/aboutfda/whatwedo/default.htm. Accessed July 25, 2011.
2. Hilts PJ. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. Chapel Hill: The University of North Carolina Press; 2004.
3. Stone PW, Horan TC, Shih H-C, et al. Comparisons of health care-associated infections identification using two mechanisms for public reporting. Am J Infect Control. 2007;35:145-149. (Pubitemid 46551332)
4. Henriksen K, Battles JB, Keyes MA, et al, eds. Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 1: Assessment). Rockville, MD: Agency for Healthcare Research and Quality; 2008; Available from: http://www.ncbi.nlm.nih.gov/books/NBK43624/; 2008.
5. Strom BL. Pharmacoepidemiology. 4th ed. West Sussex, UK: John Wiley & Sons Ltd; 2005.
6. Kelly J. Harsh criticism lobbed at FDA in Senate Vioxx hearing. Medscape Med News. 2004. Available from: http://www.theheart.org/article/367553.do.
7. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: The National Academies Press; 2006.
8. Cephalon. News Release: Cephalon receives complete response letter regarding request for expanded Fentora label for non-cancer breakthrough pain. 2008. Available at: http://investors.cephalon.com/phoenix.zhtml?c=81709&p= irol-newsArticle&ID=1197029&highlight= Accessed July 25, 2011.
9. U.S. Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. 2007. Available at: http://www.fda.gov/ RegulatoryInformation/Legislation/federalfooddrugandco smeticactfdcact/ significantamendmentstothefdcact/foodanddrugadminis trationamendmentsactof2007/ default.htm. Accessed July 25, 2011.
10. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Commitee (July 17, 2002). 2002. Available at: http://www.fda.gov/ohrms/ dockets/ac/cder02.htm#DrugSafetyRiskManagement. Accessed July 25, 2011.
11. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder03.html#DrugSafetyRiskManagement. Accessed July 25, 2011.
12. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee. 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder04.html#DrugSafetyRiskMgmt. Accessed July 25, 2011.
13. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee. 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder05.html#DrugSafetyRiskMgmt. Accessed July 25, 2011.
14. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee. 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder06.html#DrugSafetyRiskMgmt. Accessed July 25, 2011.
15. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee. 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder07.htm#DrugSafetyRiskMgmt. Accessed Juy 25, 2011.
16. U.S. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee. 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/ cder08.html#DrugSafetyRiskMgmt. Accessed July 25, 2011.
17. U.S. Food and Drug Administration. 2009 Meeting Materials, Drug Safety and Risk Management Advisory Committee. 2009. Available at: http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementAdvisoryCommittee/ucm126014.htm. Accessed July 25, 2011.
18. U.S. Food and Drug Administration. 2010 Meeting Materials, Drug Safety and Risk Management Advisory Committee. 2010. Available at: http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementAdvisoryCommittee/ucm199 874.htm. Accessed July 25, 2011.
19. U.S. Food and Drug Administration. 2011 Meeting Materials, Drug Safety and Risk Management Advisory Committee. 2011. Available at: http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementAdvisoryCommittee/ucm250 295.htm. Accessed February 25, 2012.
20. United States Government Accountability Office. Drug Safety: FDA has begun efforts to enhance postmarket safety, but additional actions are needed. Report no. GAO-10-68 Report to the Ranking Member, Committee on Finance, U.S. Senate. Washington, D.C. 2009; Available at: http://www.gao.gov/new.items/d1068. pdf.
21. U.S. Food and Drug Administration. The Future of Drug Safety- Promoting and Protecting the Health of the Public: FDA's Response to the Institute of Medicine's 2006 Report. 2007. Available at: http://www.fda. gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/UCM171627. pdf. Accessed March 22, 2012.
22. U.S. Food and Drug Administration. Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements. 2011. Available at: http://www.fda.gov/safety/medwatch/ safetyinformation/safetyalertsforhuman medicalproducts/ucm201003.htm. Accessed May 18, 2012.
23. U.S. Food and Drug Administration. Remarks at the Office of National Drug Control Policy Announcement of the Prescription Drug Abuse Action Plan. Remarks as Delivered of Margaret A. Hamburg, M.D. Commissioner of Food and Drugs Office of National Drug Control Policy Announcement of the Prescription Drug Abuse Action Plan April 19, 2011. 2011. Available at: http://www.fda.gov/NewsEvents/ Speeches/ucm254856.htm. Accessed July 25, 2011.
24. U.S. Department of Health and Human Services. Identifying CDER's Science and Research Needs Report. 2011. Available at: http://www.fda.gov/downloads/ Drugs/ScienceResearch/UCM264594.pdf. Accessed July 31, 2011.
25. Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington, DC: The National Academies Press; 2012.